Combination treatment increases survival in high-risk PCa patients
A combination of brachytherapy and external radiation plus androgen deprivation gives prostate cancer patients with high-risk disease a better chance of survival than patients treated with radiation alone, according to a study in the International Journal of Radiation Oncology*Biology*Physics (2005; 61:32-43).
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
Independent urology practices head into 2027 facing a conversion factor cut, prior authorization hurdles, and Part B drug price negotiation, according to Gary Kirsh, MD.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.